Wenjie OneTouch was originally affiliated to Johnson & Johnson Group, a century-old international brand. It is a sub-brand of Johnson & Johnson, a subsidiary of the United States that specializes in the production of blood sugar monitoring products (JPY is referred to as Johnson & Johnson's blood sugar meter for short). Now Johnson & Johnson's blood sugar meter has been renamed Wenjie blood sugar meter. In 1987, the Wenjie OneTouch brand was born, becoming a milestone in the development history of pocket blood glucose meters.

In 1994, Johnson & Johnson introduced Steady OneTouch to the Chinese market to help Chinese diabetic patients monitor and control blood sugar. Since entering the Chinese market, Wenjie OneTouch has not only been committed to continuously improving the research and development of blood sugar monitoring technology and new products, but also actively devotes itself to China's diabetes education industry. Wenjie OneTouch has established cooperative relationships with hospitals across the country to promote diabetes education; cooperates with medical associations in various provinces and cities to establish diabetes education centers; carry out self-monitoring education for diabetic patients, free diabetes diagnosis and other activities; and cooperate with the Diabetes Branch of the Chinese Medical Association , sponsors the National Diabetes Census and Diabetes Academic Conference to further popularize self-monitoring and management knowledge of diabetes. Wenjie OneTouch's contribution to China's diabetes industry has been unanimously recognized by professional medical staff and patients, and has now become a leader and innovator in the field of blood sugar monitoring. For more than 30 years, LifeScan, the manufacturer of Wenjie OneTouch products, has been unswervingly committed to improving the quality of life of patients with diabetes.

In 2019, Lefscon Group, the manufacturer of Wenjie OneTouch products, set up its Asian headquarters in Shanghai, relying on Lefscon (Shanghai) Medical Equipment Co., Ltd. to provide services to patients with diabetes in the Asia-Pacific region. Currently, there are more than 122 million diabetes patients in China, accounting for nearly one-tenth of the population. The number of diabetes patients in China ranks first in the world. Faced with such a huge market and the urgent need for blood sugar monitoring products from patients, the various blood sugar monitoring products and management solutions provided by Lefscon can just meet the performance needs of patients. At the same time, the investment in the new headquarters demonstrates the strategic significance of the Chinese market to Lefscon, and the company's determination to continue to develop and enhance its leadership in this key region.

For more than 40 years, Lefscon has been unswervingly paying attention to patients' blood sugar monitoring and management, and has made unremitting efforts in diabetes health knowledge, committed to improving the quality of life of diabetic patients. Today, Wenjie OneTouch continues to be at the forefront of R&D, promoting professional monitoring and management for diabetes, and continuously improving the research and development and creation of blood sugar monitoring technology and new products, with more than 20 million loyal users around the world. Wenjie OneTouch's contribution to the diabetes industry has been unanimously recognized by professional medical staff and patients at home and abroad.